drugset / Trial / NCT05517421
Study to Assess Batoclimab in Participants With Active Thyroid Eye Disease
RandomizedParallel-groupTriple-blindTreatment
Summary
To evaluate the efficacy of batoclimab 680 milligrams (mg) subcutaneous (SC) once a week (QW) for 12 weeks followed by 340 mg SC QW for 12 weeks versus placebo on proptosis responder rate at Week 24.
Timeline
- Start
- 2022-11-23
- Primary completion
- 2025-11-02
- Completion
- 2025-11-18
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Batoclimab | Monoclonal antibody | 340 mg | Subcutaneous |